EVENTS IN-PERSON, HYBRID OR DIGITAL? - TRENDS AND PERSPECTIVES FROM THE SPONSORS YOUR INTERNATIONAL PARTNER for Congresses, Events and Communication
←
→
Page content transcription
If your browser does not render page correctly, please read the page content below
YOUR INTERNATIONAL PARTNER for Congresses, Events and Communication EVENTS IN-PERSON, HYBRID OR DIGITAL? TRENDS AND PERSPECTIVES FROM THE SPONSORS
COMPANY
REPRESENTATIVES ANSWERS
9 1.872
208
QUESTIONS
We are at a turning point, with the reopening of in-per- more sophisticated event features, which we are cal-
son events and the planning of events for next autumn. At ling “an augmented event”. This combines some typical
this juncture, we considered it would be useful to ask cor- advantages of the online platform - such as access anywhe-
porate decision makers who sponsor events to under- re, any day and time and an expansion of the audience –
stand their attitudes and desires and devise solutions and combined with the strengths of in-persons events with an
projects more in line with the expectations of the mar- ability to involve delegates, transmit content more ef-
ket. The survey Events in-person, hybrid or digital? fectively and strengthen networking and relationships.
Trends and perspectives from the Sponsors captured The pandemic will act as a game changer for the
the viewpoints from over 200 representatives of phar- events market, where the experimentation, innovation,
maceutical and biopharma companies from across all flexibility and courage evident during the pandemic, is now
therapeutic areas. paving the way for new formats to evolve, adapting them
The results of the survey are very interesting and even more to the specific needs of each target and client.
encouraging because they reveal first and foremost that The new formats are also drawing inspiration from dif-
companies continue to believe in the benefits of ferent sectors such as TV, gaming, trade fairs, etc.), al-
in-person events and are keen to invest in this tool going lowing the event organisers identify the best solution to
ANSWER
forward. From the analysis of the responses and from the obtain the desired results, changing not only the format
dialogue that we carried out with company representati- (in-person, virtual or hybrid) but also the duration and
ves, we clearly noticed a strong trend to favour the schedule planning, the interaction among participants, the
return to in-person events, or at least to some sort of communication before, during and after the event. In short,
hybrid formats. In addition we noted that enriching virtual we are seeing several positive signs that suggest that, once
aspects of meetings with new engagement tools was also the pandemic is over, that events will emerge from the
considered important. With this in mind, we can predict crisis stronger and even more effective.
that events next autumn will involve a move towards
EVENTS IN-PERSON,
HYBRID OR DIGITAL?
TRENDS AND PERSPECTIVES
FROM THE SPONSORSTHERAPEUTICS
AREAS
ALLERGOLOGY 8%
ALTERNATIVE MEDICINES 1%
ANAESTHESIA AND INTENSIVE CARE 23%
ANGIOLOGY 1%
BIOTECHNOLOGY 4%
CARDIOVASCULAR 20%
DENTISTRY 4%
DERMATOLOGY 6%
DIABETOLOGY 4%
EMERGENCY MEDICINE 10%
ENDOCRINOLOGY 4%
GASTROENTEROLOGY 10%
GENERAL MEDICINE 9%
GENERAL SURGERY 10%
GENETICS 1%
GERIATRY 4%
GYNECOLOGY 6%
HAEMATOLOGY 8%
HYPERTENSION 5%
IMMUNOLOGY 13%
INFECTIOUS DISEASES 8%
INTERNAL MEDICINE 5%
NEPHROLOGY 8%
NEUROLOGY 9%
NEURORADIOLOGY 5%
ONCOLOGY 9%
OPHTHALMOLOGY 18%
ORTHOPEDICS 11%
OTHERS 17%
OTOLARINGOLOGY MEDICINE 5%
PAEDIATRICS 9%
PALLIATIVE CARE / PAIN THERAPY 10%
PATHOLOGY 1%
PHARMACOLOGY /PHARMACY 10%
PLASTIC SURGERY 4%
PNEUMOLOGY / RESPIRATORY DISEASE 13%
PSYCHIATRY 5%
RADIOLOGY 3%
REHABILITATION 5%
RHEUMATOLOGY 10%
SPORT MEDICINE 2%
UROLOGY/ANDROLOGY 7%
EVENTS IN-PERSON, TRENDS AND PERSPECTIVES
3 HYBRID OR DIGITAL? FROM THE SPONSORS01 02
Are you planning to attend events in person Compared to 2019, the expected
as multisponsor/monosponsor between sponsorship budget in 2021
September/December 2021? will approximately be:
80% of 2019 budget
8%
16%
NO, Other
IN PERSON ATTENDANCE 3%
WILL NOT BE POSSIBLE IN 2021
03 04
In 2021 investments on events If attending a hybrid event,
will be planned: would you rather participate to:
Mainly for monosponsor events 100%
VIRTUAL EVENT
17% 17%
Mainly for hybrid/residential attendance BOTH
31%
43%
Mainly for virtual events attendance
35% IN-PERSON
EVENT
Other 52%
5%
67% Live streaming
05 37% Q&A
24% Instant polling
In the case of a hybrid event, 46% Library and content
what kind of visibility should be active
on the virtual platform? 24% Chat audio and one to one videos
14% Lounge Area with instant chat
32% Virtual booth
24% Company meetings in breakout rooms
406 07
Please choose the most suitable According to your experience in 2020,
duration for a virtual event: in case of a virtual event please select your
6-12 hours 100% preferred type of sponsorship:
76%
82% 82%
18-24 hours
9% 60%
More than 24 hours 40%
18% 18%
2%
Less than 6 hours YES NO YES NO YES NO
13% Virtual booth Scientific Session Branding
NECESSARY NOT NECESSARY IRRELEVANT
82%
08
57%
53%
45%
Which “extra” technical features
36%
should be included in a virtual platform?
31%
27%
24%
20%
14%
4%
7%
Library with on Chat available Gaming Polling, Q&A,
demand content for delegates and to increase survey
available for 6 company staff visits to
months (at least) virtual booths
60% E-learning videos (5/10 minutes)
before and after the event
09 38% Scientific gaming
(escape rooms, simulations, etc)
48% Q&A after the event
According to the experience gained in 2020, and «focus on» with KOL
AIM Group International has developed
new scientific formats to make 50% TV format scientific sessions
virtual content more appealing. with a professional presenter
Which of the following formats 37% Double interviews
do you consider more interesting
in terms of sponsorship?
8% Thematic web radio
5 29% Take-home infographic
after the eventTHANKS
TO THE COMPANIES WHO RESPONDED
TO OUR SURVEY
BAUSCH & LOMB - IOM SPA HUMANA
INTERSURGICAL SPA
3M INNOVA
JANSSENHTS
ABBOTT INTERSURGICAL
JERGOSOFT SPA
ADI JANSSEN
JNJ
ADLER ORTHO JERGOSOFT
JOHNSON & JOHNSON SURGICAL VISION
AFERETICA SRL JNJ
KARDIA
ALFASIGMA JOHNSON
KARL STORZ & JOHNSON
ENDOSCOPIA SURGICAL
ITALIAVISION
SRL
ALK ABELLÒ KARDIA
KYOWA KIRIN
AMGEN KARL STORZ ENDOSCOPIA
LABORATORI ITALIA SRL
GUIDOTTI S.P.A.
AMOMED PHARMA SRL KYOWA KIRIN FARMACEUTICO C.T.
LABORATORIO
B BRAUN LABORATORI
LUMED GUIDOTTI S.P.A.
BAXTER LABORATORIO
MEDACTA FARMACEUTICO C.T.
BAYER LUMED
MEDTRONIC
BIOTEST ITALIA SRL MEDACTA
MINDRAY MEDICAZL ITALY SRL
BIOTRONIK ITALIA SPA MEDTRONIC
MSD
BMS MINDRAY
MT ORTHOMEDICAZL ITALY SRL
CANÈ MEDICAL TECHNOLOGY SPA MSD
MULTIOSSIGEN SPA
CARL ZEISS SPA MT
NEW ORTHO
TECH S.P.A.
CHIESI ITALIA MULTIOSSIGEN
NIDEK MEDICALSPA SRL
COMPAGNIA ITALIANA OFTALMOLOGICA NEW TECH AT
ORGANON S.P.A.
MSD
COOK NIDEK
PFIZER MEDICAL SRL
DAIICHI SANKYO ITALIA SPA NOVARTIS
PIRAMAL CRITICAL CARE ITALIA
DOC ORGANON
SAMOT RAGUSAAT MSD ONLUS
DOMPÉ PFIZER
SANDOZ
DORC PIRAMAL
SERVIZIO DICRITICAL CARE ITALIA
INFORMAZIONE SANITARIA
EDWARDS SAMOT RAGUSA ONLUS
PER I TESTIMONI DI GEOVA
EPITECH GROUP SANDOZ
SIFI
ESSITY ITALY SANOFI
SUNMEDICAL
EUKON - SMT SERVIZIO
TAKEDA DI INFORMAZIONE SANITARIA
EVOLUZIONE SRL PER I TESTIMONI DI GEOVA
TELEFLEX
FRESENIUS MEDICAL CARE ITALIA S.P.A. SIFI
TEVA
GALENO SOCIETÀ MUTUA COOPERATIVA SUNMEDICAL
THERMO FISHER SCIENTIFIC
GE HEALTHCARE TAKEDA
TILLOMED ITALIA S.R.L.
GEM TELEFLEX
UCB
GRIFOLS ITALIA S.P.A. TEVA
VISUFARMA S.P.A.
GRUNENTHAL
GUERBET SPA THERMO
WERFEN FISHER SCIENTIFIC
HAROL GSK
SRL TILLOMED
NOVARTIS ITALIA S.R.L.
GUERBET SPA
HEINE OPTOTECHNIK UCB
GRUNENTHAL
HAROL
HUMANASRL VISUFARMA
SANOFI S.P.A.
HEINE OPTOTECHNIK
INNOVA HTS WERFEN
GSKYou can also read
